Interview with Germany’s BfTG: 40% of Market Lost to Illicit Trade, Industry Calls for Smarter Regulation

Sep.20.2025
At the InterTabac trade show in Dortmund, Philip Drögemüller, Managing Director of Germany’s Smoke-Free Alliance (BfTG), spoke with 2Firsts. He said Germany’s vaping market still has substantial potential, but the industry faces policy uncertainty and compliance pressure. The association urges companies to operate compliantly and to shift from disposable products to rechargeable systems as early as possible to prepare for the structural adjustments brought by the EU battery rules in 2027.

Key Points | Conversation with BfTG

 

  • Association profile: Founded a decade ago, representing small and medium-sized vaping firms in Germany and companies operating in the German market; core work is policy advocacy and harm-reduction education.

 

  • Market potential: Germany’s smoking rate is still about 30%; with supportive harm-reduction policy, growth headroom is significant.

 

  • Policy uncertainty: The EU Tobacco Products Directive (TPD) is up for revision; future regulatory direction will profoundly affect the sector.

 

  • Industry transition: The EU 2027 battery regulation will phase out disposables; companies should invest early in rechargeable systems.

 

  • Association stance: Evidence-based advocacy and compliance leadership to help build a policy environment that supports harm reduction.

 


 

2Firsts, September 20, 2025, Dortmund, Germany —— during InterTabac in Dortmund, 2Firsts held an in-depth discussion with Philip Drögemüller, Managing Director of the German Smoke-Free Alliance (Bündnis für Tabakfreien Genuss e.V.,BfTG), on the current state of Germany’s vaping market, policy risks, and the industry outlook.

 

德展|对话德国无烟享受联盟:一次性产品将被淘汰,企业需提前布局可充电
Philip Drögemüller posing with the BfTG brochure|Image source:2Firsts

 

 

A Decade-Old Association: Focus on SMEs and Harm-Reduction Education

 

 

Founded ten years ago, BfTG represents small and medium-sized enterprises in Germany and companies doing business in the country. Its core functions are giving the industry a voice, advancing policy dialogue, and communicating the concept of tobacco harm reduction to media and the public.

 

“Many policymakers still cannot distinguish the risk differences between smoking and vaping—this is a long-term area where we must keep working,” Drögemüller noted.

 

Interview with Germany’s BfTG: 40% of Market Lost to Illicit Trade, Industry Calls for Smarter Regulation
Philip Drögemüller briefing 2Firsts on the current state of e-cigarette regulation in Germany|Image source:2Firsts

 

 

Black Market Share as High as 40%

 

 

On the current market, Drögemüller acknowledged that the legal sector faces serious challenges, with the illegal trade being the biggest threat.

 

“We estimate the black market accounts for 40% of Germany’s market. According to our survey last year, member companies lost about 30% of turnover on average,” he said.

 

The popularity of disposable products has made it easier for illegal products to enter distribution channels such as kiosks and other retail outlets.Although German customs are active in enforcement, manpower and political-structural constraints make full coverage difficult.

 

Interview with Germany’s BfTG: 40% of Market Lost to Illicit Trade, Industry Calls for Smarter Regulation
BfTG booth | Image source: 2Firsts

 

 

Flavor Bans Could Be “Devastating”

 

 

Asked whether Germany might follow the Netherlands or the UK, Drögemüller said flavor bans are “the greatest threat to the entire industry.”

 

“In early 2024, the Netherlands implemented a flavor ban. Within just three months, the legal market shrank sharply while the illicit market surged—resulting in more minors encountering unsafe products.”

 

He emphasized that flavor restrictions are likely in the coming TPD revision, so the industry must engage at the EU level to prevent one-size-fits-all extremes.

 

 

Active Advocacy: Using Scientific Facts to Persuade Policymakers

 

 

BfTG maintains dialogue with parties across Germany and is a founding member of the Independent European Vape Alliance (IEVA) at the EU level.

 

“Our method is to use scientific data and concise charts to communicate with policymakers, stressing that vaping is a harm-reduction tool for adults, not a gateway for youth,” Drögemüller said. “More politicians are willing to listen, and we’re cautiously optimistic.”

 

 

Interview with Germany’s BfTG: 40% of Market Lost to Illicit Trade, Industry Calls for Smarter Regulation
At InterTabac, the BfTG booth displayed member testimonials. Pictured is the owner of Dampfstubb, who said he joined BfTG because “sensible e-cigarette regulation is crucial, and the association represents and protects my interests.”|Image source:2Firsts

 

 

Market Potential and Policy Advice

 

 

Germany’s smoking rate remains about 30%, far higher than the UK’s 12%. Drögemüller believes that if Germany clearly supports vaping as a harm-reduction tool—as the UK has—the market still has tremendous growth potential, alongside significant reductions in public healthcare expenditures.

 

For companies, he urged strict compliance, avoiding any involvement in illicit trade, and planning an early transition from disposables to rechargeable systems, as the EU battery regulation will eliminate disposables by 2027.

 

Drögemüller concluded: “Vaping is currently the most effective smoking-cessation alternative. If it is wiped out by blanket policies, that would be a setback for public health. Our mission is to ensure compliant businesses have a stable, predictable future.”

 


For more on-the-ground coverage, visit the 2Firsts InterTabac Special Section.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05
Product | PMI Launches Three IQOS ILUMA i BEYOND Limited Editions in Japan, Retaining REMIX Pricing and Retail Channel Structure
Product | PMI Launches Three IQOS ILUMA i BEYOND Limited Editions in Japan, Retaining REMIX Pricing and Retail Channel Structure
Philip Morris Japan (PMJ) began launching three IQOS ILUMA i BEYOND limited-edition heated tobacco devices in Japan on November 18, 2026, covering PRIME, the standard ILUMA i and ONE. Suggested retail prices are ¥11,980, ¥7,980 and ¥4,980, respectively, matching the REMIX limited-edition collection introduced in June. BEYOND features blue finishes, translucent components and differentiated surface materials while retaining the existing IQOS ILUMA i device architecture. As with REMIX, all three models are available through official and specialist retail channels, while the subsequent convenience store rollout covers only the standard ILUMA i and ONE versions. The two collections share the same pricing tiers and retail distribution structure, with their principal differences in exterior design.
product
Nov.20
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
AIR Global PLC (NASDAQ: AIIR) announced on November 5, 2026, that it had submitted a Premarket Tobacco Product Application (PMTA) to the U.S. Food and Drug Administration (FDA) for Crown Switch, its rechargeable pod vape platform. First launched in Germany in November 2025, the device uses Quantum Chip atomization technology developed by Canadian vaporization technology company Greentank Innovations. German retail versions feature 2mL prefilled pods containing 18mg/mL nicotine in six flavors, while AIR has separately tested two 5% nicotine formulations intended for U.S. development. AIR invested $20 million in Greentank in July and reported approximately $3.4 million in U.S. PMTA-related regulatory costs for the first nine months of 2026. The Crown Switch application has been submitted, but the FDA has not granted marketing authorization.
product
Nov.13